Pembrolizumab Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed High-Risk Endometrial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
Ann. Oncol 2024 Sep 14;[EPub Ahead of Print], T Van Gorp, D Cibula, W Lv, F Backes, F Ortaç, K Hasegawa, K Lindemann, A Savarese, A Laenen, YM Kim, L Bodnar, MP Barretina-Ginesta, L Gilbert, B Pothuri, X Chen, MB Flores, T Levy, N Colombo, C Papadimitriou, T Buchanan, LC Hanker, G Eminowicz, L Rob, D Black, J Lichfield, G Lin, R Orlowski, S Keefe, A Lortholary, B SlomovitzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.